Abstract: The present invention relates to nucleotide sequences which encode polypeptides of antibodies against the p53 protein in vertebrates, and to die polypeptides and antibodies (or fragments thereof) encoded by those nucleotide sequences. The invention also relates to nucleotide sequences and polypeptide sequences for use in the development of diagnostic and therapeutic compositions, and to methods of using those diagnostic and therapeutic compositions in the diagnosis and treatment of cancer, rheumatoid arthritis and other disease states which exhibit abnormalities of p53.

Abstract: This invention provides therapeutic treatments that prevent or ameliorate thrombocytopenia based on administration of small RNA fragments. More specifically, this invention provides an improved chemotherapeutic regimen that prevents or ameliorates bone marrow suppression and thrombocytopenia induced by anti-cancer drugs, wherein the chemotherapeutic regimen incorporates administration of small RNA fragments. Further, the present invention provides a therapeutic treatment for thrombocytopenia associated with immune disorders known as Immune Thrombocytopenic Purpura based on administration of small RNA fragments.

Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Abstract: The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

Abstract: The present invention relates to compositions and methods for detecting and inhibiting squamous cell carcinoma using agents that target the laminin 5 alpha 3 G4-G5 domain.

Abstract: A novel protein (Gm1) includes an amino acid sequence part having a high homology with a domain having a high homology with a GTP binding site and a GTPase site conserved among G protein ? subunits and a trimer forming domain conserved among G protein ? subunits. The Gm1 protein is involved in signal transduction via a G protein-coupled receptor (GPCR) stimulation. The Gm1 protein is expressed intensively in human brain, thymus, testes, spleen, small intestine, uterus and heart. A method for screening for a substance capable of regulating a cellular signal transduction employs a polynucleotide encoding the Gm1 protein.

Abstract: The present invention relates to Imidazolopyrimidine Analogs, methods of making Imidazolopyrimidine Analogs, compositions comprising an Imidazolopyrimidine Analog, and methods for treating or preventing a PI3K-related disorder comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog. The invention also relates to methods for treating or preventing mTOR-related disorders comprising administering to a subject in need thereof an effective amount of an Imidazolopyrimidine Analog.

Abstract: A method of treating viral infections comprises administering to a patient a regimen that is able to temporarily reduce the number or functionality of the host cells which the virus uses for its reproduction in a controlled manner. Preferably, host cells are part of the immune system.

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Abstract: The invention provides a method for generating anti-CD4 auto-antibodies comprising administering to an individual an anti-CD4 antibody molecule which has a low affinity for native CD4 in said individual or a protein or peptide comprising a CD4-like epitope, wherein administration of said antibody molecule, protein or peptide results in the generation of anti-CD4 auto-antibodies.

Abstract: The present invention relates to methods for treating multiple sclerosis by combining immunotherapy with myelin repair.

Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

Abstract: The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

Abstract: The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

Abstract: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.

Abstract: The present invention relates to compounds that are able to prevent intramolecular contact of the N-terminal residues 10 to 18 of human C5aR with the extracellular loops thereof. More specifically the invention relates to compounds that are able to bind the aspartates in positions 10, 15 and 18 and the glycine in position 12 of the human C5aR. Such compounds are preferably of the general formula Xn-E-X39-K-X7Y-V-X11-Y-Xm, wherein XnX39, X7X11 and Xm are stretches of amino acids and the other letters represent the corresponding amino acids or non-proteinogenic analogs thereof. The invention further relates to their use in prophylaxis and therapy.

Abstract: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

Abstract: The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells.

Abstract: This invention provides compositions including a chimera of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. The present invention also provides complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions of this invention are also disclosed.

Abstract: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.

Abstract: The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group.

Abstract: The present invention concerns the use of the mushroom Agaricus blazei Murill for producing a medication for combating or preventing bacterial and non-bacterial infections (e.g. parasites or virus) in a mammal as well as combating or preventing allergy in mammals. Such an infection may e.g. be caused by pneumococci and even more specifically where the mammal is a human.

Abstract: Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6% by weight of an extract of Usnea barbata, containing 96% of usnic acid, and 40% by weight of an extract of Hypericum perforatum, containing 39% of hyperforin, together. The pharmaceutical composition leads to a potentiation of the anti-inflammatory and anti-microbial effects of the extracts and to stabilization of the hyperforin. The combination is suitable for the external and internal treatment of various skin diseases, in particular skin inflammations and skin ageing, and for the treatment of skin infections with pityrosporon yeast fungi, acne and rosacea.

Abstract: Promoter genes that are derived from Marek's disease virus (MDV). These promoter genes can express two foreign genes when inserted in a recombinant turkey herpesvirus (HVT). A recombinant HVT having said novel promoter gene between two foreign genes. The poultry vaccine consisting of the recombinant turkey herpesvirus described in the present invention.

Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Abstract: It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive cells to a support which has a polypeptide (P) having at least one cell-adhesive minimum amino acid sequence (X) per molecule, and is free from animal-origin components; culturing the adhesive cells in a medium free from animal-origin components; subculturing the cultured adhesive cells using a cell dispersing agent free from animal-origin components; and then inoculating and proliferating a virus in the cells obtained by culturing the adhesive cells.

Abstract: The present invention relates to the use of erythropoietin (EPO) for enhancing immune responses and for the treatment of lymphoproliferative disorders, excluding multiple myeloma. Accordingly to the invention EPO may be administered with a viral or bacterial vaccine.

Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV.

Abstract: The invention relates to methods for protecting and/or treating a mammal at risk of acquiring a condition associated with bacteria that produce a calmodulin exotoxin, a metalloproteinase exotoxin, or both, by administering a non-antibacterial tetracycline formulation.

Abstract: This invention relates to novel compositions of borulinum toxin that are stabilized using HIV-TAT fragments or derivatives of HIV-TAT fragments. The composition can be administered for various therapeutic, aesthetic and/or cosmetic purposes. The invention also provides method for stabilizing botulinum toxin using HIV-TAT fragments or derivatives or HIV-TAT fragments.

Abstract: The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal against any target immunogen, and is particularly preferred for use with immunocontraceptive vaccines such as GnRH and PZP immunocontraceptive vaccines.

Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.

Abstract: The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance.

Abstract: Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in the intact form of the composition.

Abstract: The present invention provides surface-stabilized amorphous pharmaceuticals comprising an amorphous pharmaceutical substrate coated with a biocompatible immobilizing material. Amorphous pharmaceutical substrates that are prone to surface enhanced crystallization benefit from the present coatings. The coated amorphous pharmaceuticals of the present invention maintain their amorphous state and, therefore, their solubility over extended periods of time, relative to uncoated pharmaceuticals.

Abstract: A cosmetic makeup product comprising at least two compositions, the first composition comprising a physiologically acceptable medium and the second composition comprising a mixture of at least one high molecular weight polymer having a weight-average molecular mass of greater than or equal to 200,000 g/mol and at least one low molecular weight non-volatile liquid silicone compound having a weight-average molecular mass of less than 200,000 g/mol, wherein the at least one high molecular weight polymer and the at least one low molecular weight non-volatile liquid silicone compound are present in a proportion such that the dynamic viscosity of the mixture at 25° C., measured with a Mettler RM 180 rotational viscometer, ranges from 0.1 to 120 Pa·s; a makeup method and a makeup kit comprising the cosmetic makeup product. The cosmetic makeup product may, for example, be a lipstick.

Abstract: The present invention provides a home-use insecticide formulated as an insect knockdown agent and insect killing agent that contains a useful pyrethroid compound having superior residual efficacy. The home-use insecticide contains (d)-2-methyl-4-oxo-3-(2-propynyl)-2-cyclopenten-1-yl (d)-trans-2,2-dimethyl-3-(2,2-dichlorovinyl)cyclopropanecarboxylate as an active ingredient thereof.

Abstract: Provided is a functional building board having an antimicrobial function, which retains anti-algal and antifungal agents for a long period of time in a coat on an external wall material by using several kinds of antimicrobial composite materials, and is provided with stain-proofing function to wash away stains on the external wall material, and in which the design is not largely restricted by the color of the anti-algal or antifungal paint or by the state of the coat and the design is not influenced by the coating step in the final step. The building board according to the present invention has a coat formed on the surface, and is characterized in that antimicrobial composite materials are included on the surface of the coat and a coat layer containing colloidal silica as a main component is formed, said antimicrobial composite materials being characterized in that they control generation of algae and fungi and said building board being a fiber reinforced cement board.

Abstract: A composite material comprising a substrate and a deposition product and the use of a deposition product for providing an antimicrobial effect. The substrate of the composite material is a medical device. Further, in each of the composite material and the use, the deposition product consists essentially of at least one oxidized silver species and wherein the deposition product is comprised of a compound having the formula Ag7O8X, where X is an anion.

Abstract: The present invention relates to a fibrous 3-dimensional porous scaffold via electrospinning for tissue regeneration and a method for preparing the same. The fibrous porous scaffold for tissue regeneration of the present invention characteristically has a biomimetic structure established by using electrospinning which is efficient without wasting materials and simple in handling techniques. The fibrous porous scaffold for tissue regeneration of the present invention has the size of between nanofiber and microfiber and regular form and strength, so that it facilitates 3-dimensional tissue regeneration and improves porosity at the same time with making the surface area contacting to a cell large. Therefore, the scaffold of the invention can be effectively used as a support for the cell adhesion, growth and regeneration.

Abstract: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, pharmaceutical compositions and medical devices containing such compounds and methods utilizing such compounds in the treatment of various medical conditions.

Abstract: A copolymer comprising (a) one or more pendant group segments and (b) one or more polyol segments, each of said segments being linked to one or more further segments which may be the same or different, wherein said one or more pendant group segments are the same or different and are selected from: (i) siloxane segments; (ii) segments containing phosphoryl choline or a derivative or analogue thereof; (iii) segments containing a di- or trifluoromethyl group; (iv) heparin-like segments containing a group of formula (XII) D-N?N—Ar—SO3? ??(XII) wherein D is an aliphatic or aromatic group and Ar—SO3? comprises one or more linked aryl and/or heteroaryl groups, at least one of the aryl and/or heteroaryl groups having an SO3? substituent; and (v) segments containing a group of formula (I) [P]n?-[Lys]n-Lys-[Spacer]-Lys-[Al]x ??(I) wherein: [Al] is an inert amino acid; x is 0, 1, 2 or 3; [Spacer] is a fatty acid, amino acid, peptide or PEG; [P]n?-[Lys]n is a dendritic structure formed from n lysine group

Abstract: A bone-growth stimulating composition for forming a resorbable implant, methods for making such a composition and a corresponding putty/paste material. In some embodiments of the invention, such a material includes a plurality of particles having a predetermined size and comprising a first calcium sulfate compound, a resorbable polymer in a predetermined weight ratio and a growth factor.

Abstract: Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop subsystem is capable of adjusting at least two dynamic conditions in the specimen holder or a diameter of a specimen in the specimen holder. Embodiments of methods can coat a hybrid graft with a confluent monolayer of endothelial cells by immobilizing stem cells on a hybrid hemodialysis access graft or a hybrid femoral artery bypass graft, and placing the hybrid graft in a system embodiment according to the invention under conditions effective to promote the stem cells to form a confluent monolayer on the hybrid graft and in an environment to promote the stem cells to differentiate into endothelial cells.

Abstract: According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.

Abstract: Biodegradable polymers useful for fabricating implantable medical devices and as coatings for medical devices are provided. The biodegradable polymers are biocompatible and can be tuned to provide optimum bioactive agent elution rates as well as degradation rates. Also provided are methods for making medical devices and medical device coatings using the biodegradable polymers.

Abstract: N-substituted 4-aza-caprolactone biodegradable polymers, including derivatives thereof, useful for making implantable medical devices and coatings therefore are provided. The medical devices and coatings of the present invention can also be used for in situ controlled release drug delivery and are useful for treating or preventing medical conditions such as restenosis, aneurisms and vulnerable plaque.